Evaluation of the Therapeutic Significance of Arsenite and Thalidomide in Patients with Myelodysplastic Syndrome

Abstract

Objective: To analyze the therapeutic significance of arsenite and thalidomide in patients with myelodysplastic syndrome. Methods: From August 2021 to August 2022, 80 patients with myelodysplastic syndrome were selected and randomly divided into two groups. In the control group, the drug used was thalidomide tablets, whereas in the observation group, the drug used was arsenite and thalidomide. The treatment effect was observed and evaluated. Results: Before treatment, there was no statistical significance in the blood and serological indices between the two groups. After treatment, the observation group showed better blood and serological indices than the control group (P < 0.05). The clinical efficacy of the observation group was 77.5%, while that of the control group was 50.0%. The observation group had significantly better treatment effect (P < 0.05). The incidence of adverse effects in the observation group and the control group was 5.0% and 20.0%, respectively. The observation group had significantly fewer adverse effects (P < 0.05). Conclusion: In the treatment of patients with myelodysplastic syndrome, the use of arsenite on the basis of thalidomide can effectively improve the treatment effect and optimize the levels of various blood and serological indices, with fewer adverse effects and a relatively high safety profile.